New Clinical Data Highlighting Foundation Medicine’s Next-Generation Sequencing Analysis in Breast Cancer to be Presented at SABCS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new data from its collaborations with multiple academic medical center research groups will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) taking place December 4-8, 2012 in San Antonio, Texas. These presentations highlight Foundation Medicine’s targeted next-generation sequencing platform for comprehensive molecular profiling in cancer.

“Foundation Medicine’s core commitment is towards a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the genomic and other molecular changes that contribute to their disease”

“Foundation Medicine’s core commitment is towards a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the genomic and other molecular changes that contribute to their disease,” said Gary Palmer, M.D., J.D., senior vice president, medical affairs, Foundation Medicine. “These new data, presented with our collaborators at SABCS, provide oncology thought leaders with new, deeper insight into the molecular drivers of breast cancer. We feel these findings will accelerate advances in patient care.”

The schedule for Foundation Medicine’s presentations is as follows:

Date & Time: Wednesday, December 5, 2012 at 5:00 p.m. CT

Title: Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in calling HER2 amplifications and commonly detects other clinically relevant genomic alterations

Abstract: PD02-07

Session: Poster Discussion 2 – HER2

Location: Ballroom B

Presenter: Doron Lipson, Foundation Medicine (research in collaboration with Albany Medical College)

Date & Time: Thursday, December 6, 2012 at 10:45 a.m. CT

Title: Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease

Abstract: S3-6

Session: General Session 3

Location: Exhibit Hall D

Presenter: Justin Balko, Pharm.D., Ph.D., Vanderbilt University (research in collaboration with Foundation Medicine)

Date & Time: Thursday, December 6, 2012 at 5:00 p.m. CT

Title: Next generation genomic sequencing (NGS) identifies molecular targets in inflammatory breast cancer (IBC)

Abstract: PD05-01

Session: Poster Discussion 5 – Clinical Sequencing

Location: Ballroom A

Presenter: Massimo Cristofanilli, M.D., FACP, Fox Chase Cancer Center (research in collaboration with Foundation Medicine)

Date & Time: Thursday, December 6, 2012 at 5:00 p.m. CT

Title: What is the appropriate sample(s) on which to perform sequencing for mutational analysis to guide the selection of targeted therapy?

Abstract: PD05-03

Session: Poster Discussion 5 – Clinical Sequencing

Location: Ballroom A

Presenter: Katherine Alpaugh, Ph.D., Fox Chase Cancer Center (research in collaboration with Foundation Medicine)

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical assay, FoundationOne^TM, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.foundationmedicine.com.

Foundation Medicine® is a registered trademark, and FoundationOne^TM is a trademark of Foundation Medicine, Inc.